JP2024509193A - 銅障害の処置 - Google Patents

銅障害の処置 Download PDF

Info

Publication number
JP2024509193A
JP2024509193A JP2023553584A JP2023553584A JP2024509193A JP 2024509193 A JP2024509193 A JP 2024509193A JP 2023553584 A JP2023553584 A JP 2023553584A JP 2023553584 A JP2023553584 A JP 2023553584A JP 2024509193 A JP2024509193 A JP 2024509193A
Authority
JP
Japan
Prior art keywords
copper
triethylenetetramine disuccinate
triethylenetetramine
manufacture
disuccinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509193A5 (https=
Inventor
ジョゼフ フォーチュナク，
ガース クーパー，
マーガレット クーパー，
Original Assignee
フィリーラ ニュー ジーランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フィリーラ ニュー ジーランド リミテッド filed Critical フィリーラ ニュー ジーランド リミテッド
Publication of JP2024509193A publication Critical patent/JP2024509193A/ja
Publication of JP2024509193A5 publication Critical patent/JP2024509193A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Conductive Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023553584A 2021-03-05 2022-03-04 銅障害の処置 Pending JP2024509193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163157539P 2021-03-05 2021-03-05
US63/157,539 2021-03-05
PCT/US2022/019025 WO2022187709A1 (en) 2021-03-05 2022-03-04 Treatment of copper disorders

Publications (2)

Publication Number Publication Date
JP2024509193A true JP2024509193A (ja) 2024-02-29
JP2024509193A5 JP2024509193A5 (https=) 2025-01-24

Family

ID=83115853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553584A Pending JP2024509193A (ja) 2021-03-05 2022-03-04 銅障害の処置

Country Status (7)

Country Link
US (2) US20220280451A1 (https=)
EP (1) EP4301350A4 (https=)
JP (1) JP2024509193A (https=)
CN (1) CN117157064A (https=)
AU (1) AU2022231038A1 (https=)
CA (1) CA3212016A1 (https=)
WO (1) WO2022187709A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023255339A1 (en) * 2022-04-19 2024-12-05 Sasha A. PHILBERT Treatment of brain copper disorders
CN118987254A (zh) * 2024-08-15 2024-11-22 沈阳药科大学 一种基于双金属纳米点-溶瘤病毒静脉递送系统及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093542A1 (en) * 2007-10-04 2009-04-09 Cooper Garth J S Copper antagonist compositions
JP2018531931A (ja) * 2015-09-24 2018-11-01 イノライフ カンパニー， リミテッド 虚血組織に銅を送達するためのトリエンチンの使用
US20200148647A1 (en) * 2004-07-19 2020-05-14 Philera New Zealand Limited Synthesis of Triethylenetetramines
WO2020257279A1 (en) * 2019-06-17 2020-12-24 Philera New Zealand Ltd. Combination treatments for central nervous system disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875522A1 (en) * 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
WO2006104396A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Pre-complexed copper antagonist compositions
CA3018698A1 (en) * 2005-11-09 2007-05-18 Philera New Zealand Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
WO2017213524A1 (en) * 2016-06-10 2017-12-14 Garth Cooper Treatment of neurodegenerative disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200148647A1 (en) * 2004-07-19 2020-05-14 Philera New Zealand Limited Synthesis of Triethylenetetramines
US20090093542A1 (en) * 2007-10-04 2009-04-09 Cooper Garth J S Copper antagonist compositions
JP2018531931A (ja) * 2015-09-24 2018-11-01 イノライフ カンパニー， リミテッド 虚血組織に銅を送達するためのトリエンチンの使用
WO2020257279A1 (en) * 2019-06-17 2020-12-24 Philera New Zealand Ltd. Combination treatments for central nervous system disorders

Also Published As

Publication number Publication date
US20250114312A1 (en) 2025-04-10
EP4301350A4 (en) 2025-04-09
WO2022187709A1 (en) 2022-09-09
CA3212016A1 (en) 2022-09-09
US20220280451A1 (en) 2022-09-08
CN117157064A (zh) 2023-12-01
AU2022231038A1 (en) 2023-09-21
EP4301350A1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
US20250114312A1 (en) Treatment of copper disorders
ES2863996T3 (es) Terapia de combinación para el tratamiento del cáncer
EP3288561B1 (en) Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
JP6067203B2 (ja) ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用
Boustany-Kari et al. A soluble guanylate cyclase activator inhibits the progression of diabetic nephropathy in the ZSF1 rat
US9925154B2 (en) Cysteamine in the treatment of fibrotic disease
JP2025066802A (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
HUE032100T2 (en) A pharmaceutical composition comprising an HDAC inhibitor and a steroid and its use
CN108697678A (zh) sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用
Bishnoi et al. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia—a biochemical and neurochemical study
ES2689906T3 (es) Meglumina para reducir los niveles altos de triglicéridos
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
Smith Drugs and pharmaceuticals: management of intoxication and antidotes
KR20200056399A (ko) 요소 회로 장애를 치료하는 방법
CN113476432B (zh) J147在制备治疗和/或预防色素增多性疾病的药物/化妆品的用途
CN117327067A (zh) 一种小分子化合物epic-1042、药物组合物及其制备方法和应用
JP5634985B2 (ja) インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物
CN118453879B (zh) 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用
US12533394B2 (en) Compositions and methods for treating metabolic disorders
US12465609B2 (en) Methods of treating patients suffering from a disease condition or disorder that is associated with an increased glutamate level
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
EP4719402A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
CN105797132A (zh) 沙奎拉韦的医药新用途
TW202604485A (zh) 患有肝損傷患者肝疾病之治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260212